openPR Logo
Press release

Generic Oncology Drugs Market Insights with Key Company’s Profiles - Forecast to 2028 | GmbH, AstraZeneca, Hoffmann-La Roche Ltd., Eli Lily and Company, ARIAD Pharmaceuticals

02-28-2019 03:22 PM CET | Health & Medicine

Press release from: Future Market Insights

Generic Oncology Drugs Market Insights with Key Company’s

Generic oncology drugs, being able to detect and treat tumors, are utilized extensively in the healthcare industry for treating cancer. Notable enhancements in the technology with the blend of information is expected to accelerate the pace of growth for the generic oncology drugs market and the cost pertaining to the treatment of cancer. Advanced technologies such as real world data, mobile apps, and artificial intelligence have successfully been able to achieve a high engagement rate of the patients, which has resulted in increasing awareness of the cancer treatment among the patients.

A significant increase has been noted in the spending capacity for the development of cancer. More than one-third of the trials proposed by the manufacturers are aimed at offering personalized cancer treatments, which further propels the demand for generic oncology drugs. A host of these factors have contributed massively to the expansion of the generic oncology drugs market at the global level.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8961

According to a report, the global generic oncology market is poised to surpass a striking CAGR of 6% through 2028. Increasing inclination of individuals towards smoking and tobacco consumption is the chief cause of cancer. Secondary factors such as sedentary lifestyle, genetic causes, viral infections, carcinogens, and high consumption of junk food make the human body susceptible to cancer. Growing concerns of a high number of deaths occurring on the back of cancer have provoked the government authorities to take effective steps for preventing cancer.

Notable Developments in the Generic Oncology Drugs Market

Improvement in the cancer treatment drugs and therapies have been one of the most underlying aims of the pharmaceuticals and medical organizations operating at the global level. Consequently, generic oncology drugs have been utilized for innovating novel therapies and increasing the survival rates of patients.

Blood Cancer Immensely Contributes to the Growth of the Generic Oncology Drugs Market

Amongst the various types of cancer such as skin cancer, bladder cancer, bone cancer, eye cancer, gastrointestinal cancer, gynecological cancer, lung cancer, endocrine cancer, and blood cancer is accounted for generating the largest share for the generic oncology drugs market. Patients diagnosed with blood cancer seek complete treatment to this chronic disease, as a result of which excessive demand for generic oncology drugs is created. In addition to this, the high cost of the therapies and generic oncology drugs play a crucial role in the growing size of the generic oncology drugs market.

Recent Developments to Drive the Growth of the Generic Oncology Drugs Market

The key players involved in transforming the landscape of the generic oncology drugs market include Bayer Healthcare AG, Amgen, Teva Pharmaceutical Industries, Pfizer, Boehringer Ingelheim GmbH, AstraZeneca, Hoffmann-La Roche Ltd., Eli Lily and Company, ARIAD Pharmaceuticals, Inc., GlaxoSmithKline, CELGENE Corporation, Novartis AG, Johnson and Johnson, AbbVie Inc., Merck & Co., and Sanofi, among others.

A Methodology of this Report is Available upon Request @ https://www.futuremarketinsights.com/askus/rep-gb-8961

Out of these leading players, CELGENE, Novartis, and Roche have been procuring a considerable share in the generic oncology drugs market with a rich product portfolio and pipeline products aimed at treating cancer effectively.

Novartis AG applied smart strategies for channel integration like eCommerce with mobile application to fuel the sales at the retail stores. In addition to this, the company achieved a CE mark for its gene modifying therapy used for the treatment of blood cancer.

Pfizer Inc. has been focusing on the over 39 therapies, in order to fortify its product portfolio. In the year 2017, Glasdegib of Pfizer received the priority review from the U.S. FDA to treat myeloid leukemia. Post this, XTANDI of Pfizer as well received the FDA approval.

Click Here For Full Report: https://www.futuremarketinsights.com/reports/generic-oncology-drugs-market

About Us

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us

U.S. Office

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

Email: sales@futuremarketinsights.com

Web: https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Generic Oncology Drugs Market Insights with Key Company’s Profiles - Forecast to 2028 | GmbH, AstraZeneca, Hoffmann-La Roche Ltd., Eli Lily and Company, ARIAD Pharmaceuticals here

News-ID: 1624496 • Views:

More Releases from Future Market Insights

Japan Caramel Food Colors Industry Outlook to 2036: Strategic Insights for R&D, Expansion, and Market Development
Japan Caramel Food Colors Industry Outlook to 2036: Strategic Insights for R&D, …
The Japanese caramel food colors market is on a steady growth trajectory, with demand projected to rise from USD 11.2 million in 2025 to USD 28.4 million by 2035, registering a CAGR of 9.8%. The initial phase of the forecast period (2025-2030) anticipates a steady increase in demand, reaching approximately USD 17.8 million by 2030, driven by the expanding use of caramel colors across confectionery, dairy, and baked goods. The market's
Comprehensive Analysis of the Japan Butter Flavor Market: Technology Evolution, Regional Demand & Forecast Scenarios to 2036
Comprehensive Analysis of the Japan Butter Flavor Market: Technology Evolution, …
The demand for butter flavor in Japan is projected to rise from USD 16.1 million in 2025 to USD 29.4 million by 2035, reflecting a steady compound annual growth rate (CAGR) of 6.2%. This growth is underpinned by increasing adoption across bakery products, confectionery items, and dairy-based preparations, as manufacturers seek to enhance taste experiences and deliver authentic dairy character in a wide range of food offerings. The Japanese bakery and
Japan Casein Peptone Market Deep-Dive 2026-2036: Strategic Forecasts, Market Entry Insights & Emerging Opportunities
Japan Casein Peptone Market Deep-Dive 2026-2036: Strategic Forecasts, Market Ent …
The demand for casein peptone in Japan is projected to grow steadily, reaching USD 27.1 million by 2035, up from USD 20.6 million in 2025, reflecting a compound annual growth rate (CAGR) of 2.8%. During the early forecast period (2025-2030), demand is expected to rise from USD 20.6 million to approximately USD 23.6 million, supported by its widespread applications in biotechnology, pharmaceuticals, and food industries. Casein peptone continues to play
Global Boride Powder Market Size, Share & Forecast: High-Growth Segments, Value Chain Insights & Opportunity Mapping
Global Boride Powder Market Size, Share & Forecast: High-Growth Segments, Value …
The global boride powder market is valued at USD 19.7 billion in 2025 and is projected to reach USD 32.2 billion by 2035, advancing at a steady 5.0% CAGR over the forecast period. This upward trajectory reflects increasing adoption of boride-based compounds in aerospace technology, high-temperature processing environments, and advanced coating applications, where exceptional thermal stability, corrosion resistance, and mechanical strength are essential for operational performance and product reliability. Key Market

All 5 Releases


More Releases for Generic

Prominent Generic Oncology Drugs Market Trend for 2025: Novel Formulations Trans …
Which drivers are expected to have the greatest impact on the over the generic oncology drugs market's growth? The upward trend in cancer incidence is predicted to fuel the expansion of the generic oncology drugs market. Cancer, characterized by unregulated cell proliferation affecting numerous organs, results in considerable morbidity and mortality globally. The provision of affordable generic oncology drugs is an instrumental factor in cancer care, expanding access to vital treatments,
Generic Theater Presents Flyin' West
NORFOLK, VA (August 2023) - Generic Theater inaugurates its 43rd season with Flyin' West, written by award-winning playwright and New York Times bestselling author Pearl Cleage. Terrance Afer-Anderson directs this production, running weekends September 8th - October 1st at Generic Theater, Norfolk's underground theater located in the basement of Chrysler Hall. Following the end of the Civil War, many former slaves took advantage of The Homestead Act and went West to
Generic Injectables Market growth is attributed to the increasing demand for Onc …
According to Precision Business Insights (PBI), the latest report, the generic injectables market will be worth USD 22.0 billion in 2022, growing at an 11.0% CAGR from 2022 to 2028. The global generic injectables market is segmented into the following types: Product Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Immunoglobulins, Peptide Antibiotics, Vaccines, and Others), Indication (Diabetes, Cancer, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Distribution Channel (Hospital
A Demand On Generic Drugs Market And The Need To Push The Market Of Generic Drug …
Global Generic Drugs Market A generic drug is pharmaceutical drug, which is bio-equivalent to a branded drug in all forms such as route of administration, strength, dosage, quality, intended use and performance. Generic drugs are usually approved after patent expiration of patent drugs. Generic drugs are safe, effective and FDA approved. The global market is filled with 44% of generic drugs. The global generic drugs market is driven by the rise of
Generic Drug Market: Global Generic Drug Share to Reach USD 380.60 Billion by 20 …
Zion Market Research has published a new report titled “Generic Drug Market by Brand (Pure Generic and Branded Generic) for Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory and Others Therapeutic Applications - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global generic drug market accounted for around USD 200.20 billion in 2015 and is expected to reach approximately USD 380.60 billion by
Generic Drugs: Global Collaboration Opportunities
Collaboration is the key to growth With the recent economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems. At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of